Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Philip Morris to consider stake sale in biggest pharma unit - WSJ

Published 20/09/2023, 02:37
© Reuters. FILE PHOTO: The company's logo is seen near the Philip Morris Izhora factory outside Saint Petersburg, Russia April 9, 2022. REUTERS/REUTERS PHOTOGRAPHER
DBKGn
-
PM
-

(Reuters) -Marlboro maker Philip Morris (NYSE:PM) International is considering selling a stake in Vectura, its biggest pharmaceutical unit, the Wall Street Journal reported on Tuesday.

The tobacco company told the Journal that it was looking to bring on a partner to help operate and grow Vectura’s drug manufacturing outsourcing business, and could possibly sell a majority or a minority stake.

Other options include a licensing or royalties deal or a commercial partnership, the report added.

A Philip Morris spokesperson said the company did not have any comment to provide on the WSJ story.

Philip Morris bought UK-based Vectura, which makes asthma inhalers, for 1.1 billion pounds ($1.36 billion) two years ago, saying it was a part of its long-term plan to switch to being a "broader healthcare and wellness" company.

It also acquired nicotine gum maker Fertin Pharma for over $800 million and respiratory drug development company OtiTopic in the same year.

WSJ said that the tobacco giant has now had discussions with Deutsche Bank (ETR:DBKGn) on a range of options to grow its healthcare and wellness division.

In the second quarter this year, Philip Morris booked a total impairment charge of $680 million for the segment, and expected to postpone its 2025 target to reach over $1 billion of net revenues due to issues with the unit.

© Reuters. FILE PHOTO: The company's logo is seen near the Philip Morris Izhora factory outside Saint Petersburg, Russia April 9, 2022. REUTERS/REUTERS PHOTOGRAPHER

"We aim to accelerate Vectura’s growth and will be exploring potential partnerships to enhance its contract development and manufacturing organization business," Chief Financial Officer Emmanuel Babeau had said in July, adding the company remained committed to developing the wellness healthcare segment.

($1 = 0.8076 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.